CTRI/2012/08/002941已完成4 期
A randomized, open label, prospective, two arm, comparative multicentric study to evaluate the efficacy and safety of montelukast and fexofenadine fixed dose combination vs montelukast and levocetirizine fixed dose combination in the management of patients with allergic rhinitis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 4
- 主要终点
- •The change in Total Symptom Score [(TSS is the sum Total nasal symptom score (TNSS) and Total Ocular symptom score (TOSS)] at the end of study as compared to baseline
研究概览
简要总结
It is an randomized, open label, prospective, two arm, comparative multicentric study to evaluate the efficacy and safety of montelukast and fexofenadine fixed dose combination vs montelukast and levocetirizine fixed dose combination in the management of patients with allergic rhinitis.
Primary Endpointsxml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /
- The change in Total Symptom Score [(TSS is the sum Total nasal symptom score (TNSS) and Total Ocular symptom score (TOSS)] at the end of study as compared to baseline.
Secondary Endpoints
- Total nasal symptom score (TNSS) *(*nasal congestion, rhinorrhea, nasal itching, and sneezing) at the end of study as compared to baseline
- Total Ocular symptom score (TOSS) (Itching/burning eyes, tearing/watering eyes and eye redness) at the end of study as compared to baseline
- Physician’s and Patient’s Global assessment for efficacy and tolerability
- To evaluate the safety by assessing the type, number, frequency and proportion of patients with Adverse Event(s) during the study.
Total nasal symptom score (TNSS) and Total Ocular symptom score (TOSS) will be graded on 4-point categoric scale:
0 = none/ no symptoms;
1 = mild symptoms, but not affecting any activities during the day/sleep at night;
2 = moderate symptoms affecting at least one activity or disturbing sleep;
3 = severe symptoms affecting >2 daily activities or disturbing sleep all night or most of the night
研究设计
- 研究类型
- Interventional
- 分配方式
- Permuted block randomization, variable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Males and females patients more than 18 years of age.
- •2.Patients with diagnosis of Allergic Rhinitis (patients with a total nasal symptom score (TNSS; the sum of all the 4 individual nasal symptom scores) of 6 or greater and/or a total ocular symptom score (TOSS; the sum of all the 3 individual ocular symptom scores) of 4 or greater.) 3.Except Allergic Rhinitis, patients must be in general good health based on screening.
- •4.Patients having bronchial symptoms along with Allergic Rhinitis are also allowed to participate in the study.
- •5.Patients must give written informed consent after reading the Patient Information sheet and Informed Consent Form and having had the opportunity to discuss the study with the Investigator.
- •6.Patient willing to follow up and comply with the Protocol requirements.
排除标准
- •1.Males and females patients less than 18 years of age.
- •2.Pregnant and lactating women patients.
- •3.Patients not willing to comply with the study protocol and provide written informed consent to participate.
- •4.Patient with severe asthma requiring emergency room treatment within 1 month or hospitalization within 3 month before the trial.
- •5.Patients with upper respiratory tract infection or acute or chronic pulmonary disorder.
- •6.Patients with known hypersensitivity to Montelukast or Fexofenadine or other piperazine derivatives.
- •7.Expected use of any other medications for allergic rhinitis or conjunctivitis during the treatment period e.g. antihistamines, corticosteroids (inhaled, oral, parenteral, nasal and ophthalmic), cromolyn sodium, nedocromil and inhaled cholinergics.
- •8.Medications that could affect nasal or ocular symptoms including decongestants and anti-inflammatory drugs are not permitted.
- •9.No allergic rhinitis rescue medications are permitted during the study.
- •10.Patient not willing to participate in the trial.
结局指标
主要结局
•The change in Total Symptom Score [(TSS is the sum Total nasal symptom score (TNSS) and Total Ocular symptom score (TOSS)] at the end of study as compared to baseline
时间窗: baseline, Day 7 and Day 14
次要结局
- •Total nasal symptom score (TNSS) (nasal congestion, rhinorrhea, nasal itching, and sneezing) at the end of study as compared to baseline(Baseline, Day 7 and Day 14)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
不适用
Clinical Evaluation of NiTiDent Tuah Porous NiTi Dental ImplantsPartial-edentulismNCT04618055Nitium Technology Sdn Bhd105
已完成
3 期
A clinical trial to study the effects of two drugs, Tolperisone and Diclofenac in patients suffering from acute muscle spasmsCTRI/2010/091/006069Themis Medicare Limited200
已完成
2 期
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)Critical Limb IschemiaBuerger DiseaseThromboangiitis ObliteransAtherosclerosis ObliteransNCT02501018Lisata Therapeutics, Inc.33
未知
4 期
A clinical trial to study the effect of, Fluticasone Nasal Spray BP (Mfd. By Biodeal Laboratories Pvt. Ltd.) Vs Fluticasone Nasal Spray BP (Mfd. By Glaxosmithkline Pharmaceuticals Ltd) in patients with Allergic RhinitisCTRI/2010/091/000135Biodeal Laboratories Pvt. Ltd508, G.I.D.C Estate, Wadhwan City, Dist Surendranagar,Gujarat - 363035125
已完成
1 期
A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)Healthy VolunteersNCT02996019Genentech, Inc.180